Funded Startups in Natick
Among the 15 most recent Natick-funded entries shown, the largest disclosed round is Electric Hydrogen at $100M on 2024-05-09, which is a clear outlier abo…
Among the 15 most recent Natick-funded entries shown, the largest disclosed round is Electric Hydrogen at $100M on 2024-05-09, which is a clear outlier above the next-largest disclosed amounts (Stellaromics at $80M on 2025-02-11, Mercy BioAnalytics at $41M on 2023-04-03, and Colossus at $36M on 2022-01-18). The majority of disclosed dollars cluster in life-sciences: 6 of 15 entries are Biotechnology (Curadel Surgical Innovations, NeuroDex, Arch Therapeutics, Mercy BioAnalytics, PIC Therapeutics, Nirogy Therapeutics, Pillar Biosciences), alongside another 3 that sit in Health Care / Healthcare-adjacent categories (Uwill, Empassion Health, and Uwill’s classification as Health Care).
The list also shows a temporal concentration in 2023: multiple biotech and healthcare rounds land between 2023-03-20 (Empassion Health at $20M) and 2023-09-07 (Arch Therapeutics at $3M), while the disclosed rounds span a long edge from Pillar Biosciences on 2020-05-12 ($30M) up to Curadel Surgical Innovations on 2025-10-12 ($14M). Classification-wise, “Series Unknown” appears in 8 of 15 rows and “undisclosed” appears in 2 of 15 rows, while the remaining labeled rounds include Series A (5 rows) and Series B (1 row).
Most recent rounds
15 shownRelated listings
Frequently asked
What stands out as the largest disclosed round in Natick, and how much bigger is it than the rest?
Electric Hydrogen’s $100M round on 2024-05-09 is the top disclosed amount in the 15-row view; it is notably above the next-largest disclosed amounts such as Stellaromics ($80M, 2025-02-11) and Mercy BioAnalytics ($41M, 2023-04-03).
Do the rounds cluster in time, or are they spread out evenly across 2020–2025?
They’re spread across a broad window from 2020-05-12 (Pillar Biosciences, $30M) through 2025-10-12 (Curadel Surgical Innovations, $14M), but 2023 shows clustering: for example, Empassion Health ($20M, 2023-03-20), Mercy BioAnalytics ($41M, 2023-04-03), PIC Therapeutics’ $35M round is in 2022-10-19, and Arch Therapeutics ($3M, 2023-09-07) all sit within that 2023 middle stretch.
Which sectors are over-represented in this Natick list?
Biotechnology dominates the entries at 7 of 15 rows (Curadel Surgical Innovations, NeuroDex, Arch Therapeutics, Mercy BioAnalytics, PIC Therapeutics, Nirogy Therapeutics, and Pillar Biosciences). Energy appears in 2 entries (Electric Hydrogen and Colossus), and other categories generally appear once (e.g., Data and Analytics with CapeSym at $1M on 2024-02-20).
How often are stage labels missing or not reported?
“Series Unknown” appears in 8 of 15 rows (including Curadel Surgical Innovations on 2025-10-12 at $14M and Electric Hydrogen on 2024-05-09 at $100M). Separately, the amount is “undisclosed” in 2 of 15 rows (NeuroDex on 2024-11-07, and Family Promise Metrowest on 2023-06-21), which limits comparisons that rely on disclosed dollars.
Are there outliers besides the largest round—either very small disclosed amounts or unusually different sectors?
The lowest disclosed amount is CapeSym at $1M on 2024-02-20, which sits far below the otherwise biotech-heavy distribution that includes larger rounds like Mercy BioAnalytics at $41M (2023-04-03) and PIC Therapeutics at $35M (2022-10-19). On sector mix, Energy shows up only twice (Electric Hydrogen $100M and Colossus $36M on 2022-01-18), making it less represented than Biotechnology but with large disclosed rounds.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.